



## VistaGen Therapeutics to Participate in Upcoming Investor Conferences in March

March 16, 2021

SOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- [VistaGen Therapeutics](#) (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that [Shawn Singh, VistaGen's Chief Executive Officer](#), will participate in the following investor conferences in March:

### Maxim Group and M-Vest's Inaugural Emerging Growth Virtual Conference

**Dates:** March 17<sup>th</sup> – 19<sup>th</sup>

**Format:** Corporate Presentation & One-on-One Fireside Chat

**Date:** Friday, March 19<sup>th</sup> at 1:00 p.m. ET

**Format:** Fireside Chat with Jason McCarthy, Research Analyst

**Website:** To attend the virtual conference, register [here](#)  
<https://www.m-vest.com/events/2021-emerging-growth-virtual-conference>

### Benzinga Biotech Small Cap Conference

**Date:** Thursday, March 25<sup>th</sup> at 10:05 a.m. ET

**Format:** Corporate Presentation

**Website:** To attend the virtual conference, register [here](#)  
<https://events.benzinga.com/registration-page16068526119171607978331877>

For more information regarding the conferences, please visit the sponsor conference websites.

### About VistaGen

VistaGen Therapeutics is a biopharmaceutical company committed to developing and commercializing innovative medicines with the potential to go beyond the current standard of care for anxiety, depression, and other CNS disorders. Each of VistaGen's three drug candidates has a differentiated potential mechanism of action, has been well-tolerated in all clinical studies to date and has therapeutic potential in multiple CNS markets. For more information, please visit [www.vistagen.com](http://www.vistagen.com) and connect with VistaGen on Twitter, LinkedIn, and Facebook.

### Company Contact

Mark A. McPartland  
VistaGen Therapeutics, Inc.  
Phone: +1 (650) 577-3600  
Email: [IR@vistagen.com](mailto:IR@vistagen.com)



Source: VistaGen Therapeutics, Inc.

Released March 16, 2021